In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1

Journal of Clinical Microbiology

Volumn 49, Issue 1, 2011, Pages 201-208

  Knapp, David J H F ^a   Harrigan, P Richard ^a,b   Poon, Art F Y ^a   Brumme, Zabrina L ^a,c   Brockman, Mark ^a,c   Cheung, Peter K ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BEVIRIMAT;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEASIBILITY STUDY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SCREENING; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV-1; HUMANS; MUTATION, MISSENSE; RNA, VIRAL; SELECTION, GENETIC; SERIAL PASSAGE; SUCCINATES; TRITERPENES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650883987     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01868-10     Document Type: Article

References (28)

1. Adamson, C. S., et al. 2006. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat). J. Virol. 80: 10957-10971.
2. Adamson, C. S., K. Waki, S. D. Ablan, K. Salzwedel, and E. O. Freed. 2009. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J. Virol. 83:4884-4894.
3. Blair, W. S., et al. 2009. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob. Agents Chemother. 53:5080-5087.
4. Brockman, M. A., et al. 2010. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity but may be largely compensated in chronic infection. J. Virol. 84:11937-11949.
5. Reference deleted.
6. Camacho, C., et al. 2009. BLAST+: architecture and applications. BMC Bioinformatics 10:421.
7. Chackerian, B., E. M. Long, P. A. Luciw, and J. Overbaugh. 1997. HIV-1 coreceptors participate in postentry stages of the virus replication cycle and function in SIV infection. J. Virol. 71:3932-3939.
8. Choe, S. S., et al. 2008. Measurement of maturation inhibitor susceptibility using the PhenoSense HIV assay. Abstr. XVth Conf. Retrovir. Opportunistic Infect., abstr. 880.
9. Fletcher, R. 1970. A new approach to variable metric algorithms. Comp. J. 13:317-322.
10. Harrigan, P. R., et al. 2002. Performance of RE-Call basecalling software for high-throughput HIV drug resistance basecalling using "in-house" methods. Abstr. XIV Int. AIDS Conf., abstr. TuPeB4598.
11. Harrigan, P. R., et al. 2005. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J. Infect. Dis. 191:339-347.
12. Kimura, M. 1956. Rules for testing stability of a selective polymorphism. Proc. Natl. Acad. Sci. U. S. A. 42:336-340.
13. Korber, B. T., et al. 1994. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 68:7467-7481.
14. Li, F., et al. 2003. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. U. S. A. 100:13555-13560.
15. Malet, I., et al. 2007. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J. Infect. 54:367-374.
16. Malet, I., et al. 2007. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS 21: 871-873.
17. Margot, N. A., C. S. Gibbs, and M. D. Miller. 2010. Phenotypic susceptibility to bevirimat among HIV-1-infected patient isolates without prior exposure to bevirimat. Antimicrob. Agents Chemother. 54:2345-2353.
18. Martin, D., and E. Rybicki. 2000. RDP: detection of recombination amongst aligned sequences. Bioinformatics 16:562-563.
19. Martin, D. E., K. Salzwedel, and G. P. Allaway. 2008. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir. Chem. Chemother. 19:107-113.
20. McCallister, S., et al. 2008. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir. Ther. 13(Suppl. 3):A10.
21. Miura, T., et al. 2009. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J. Virol. 83:140-149.
22. Miura, T., et al. 2010. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J. Virol. 84:7581-7591.
23. Seclén, E., et al. 2010. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to bevirimat, an HIV-1 maturation inhibitor. AIDS 24:467-469.
24. Smith, P. F., et al. 2007. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother. 51:3574-3581.
25. Smith, T. F., and M. S. Waterman. 1981. Identification of common molecular subsequences. J. Mol. Biol. 147:195-197.
26. Van Baelen, K., et al. 2009. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob. Agents Chemother. 53: 2185-2188.
27. Verheyen, J., et al. 2010. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS 24:669-673.
28. Zhou, J., et al. 2004. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J. Virol. 78:922-929.